TLX — Telix Pharmaceuticals Limited
$3.5B market cap · 6 upcoming readouts tracked
Clinical trial readout dates for Telix Pharmaceuticals Limited, compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is January 2027 .
Next readout January 2027 in ~2 months
Upcoming readouts 6 5 Phase 3
Market cap $3.5B
Upcoming readouts Phase 3 68Ga-PSMA-11 January 2027Ongoing
Phase 3 177Lu-TLX250 ccRCC; Renal Cell Carcinoma (Kidney Cancer) ·
NCT07197580 August 2027Recruiting
Phase 3 177Lu-TLX591 Metastatic Castration-resistant Prostate Cancer ·
NCT06520345 December 2027Recruiting
Phase 3 Floretyrosine F 18 ([18F]FET) April 2028Not Yet Recruiting
Phase 3 TLX-101-Tx + Lomustine July 2028Recruiting
Phase 2 177Lu-TLX250 ccRCC; Renal Cell Carcinoma (Kidney Cancer) ·
NCT07870746 December 2028Not Yet Recruiting
Companies working on similar indications CELC Celcuity Inc.castration, prostate, cancer EXEL Exelixis Inc.carcinoma, renal, cell UTHR United Therapeutics Corporationkidney, renal RCUS Arcus Biosciences Inc.carcinoma, renal, cell BNTX BioNTech SEglioblastoma, cell, cancer NVCR NovoCure Limitedglioblastoma, cell, cancer
Discussion No messages yet. If you follow TLX, you can start the conversation.
Track TLX in real time
See live implied volatility for
TLX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on TLX
Trial data from ClinicalTrials.gov
(U.S. National Library of Medicine); filings and reported financials from
SEC EDGAR — U.S. government
works in the public domain. Dates are study-reported primary completion dates,
which routinely shift and are not results-release dates. Information only, not
investment advice.